121 related articles for article (PubMed ID: 7737334)
1. The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat.
Schmidt CJ; Fadayel GM
Eur J Pharmacol; 1995 Feb; 273(3):273-9. PubMed ID: 7737334
[TBL] [Abstract][Full Text] [Related]
2. Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex.
Pehek EA; Nocjar C; Roth BL; Byrd TA; Mabrouk OS
Neuropsychopharmacology; 2006 Feb; 31(2):265-77. PubMed ID: 15999145
[TBL] [Abstract][Full Text] [Related]
3. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens.
Ichikawa J; Kuroki T; Dai J; Meltzer HY
Eur J Pharmacol; 1998 Jun; 351(2):163-71. PubMed ID: 9686999
[TBL] [Abstract][Full Text] [Related]
4. M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex.
Pehek EA; McFarlane HG; Maguschak K; Price B; Pluto CP
Brain Res; 2001 Jan; 888(1):51-59. PubMed ID: 11146051
[TBL] [Abstract][Full Text] [Related]
5. Excitation of interneurons in piriform cortex by 5-hydroxytryptamine: blockade by MDL 100,907, a highly selective 5-HT2A receptor antagonist.
Marek GJ; Aghajanian GK
Eur J Pharmacol; 1994 Jul; 259(2):137-41. PubMed ID: 7957607
[TBL] [Abstract][Full Text] [Related]
6. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
[TBL] [Abstract][Full Text] [Related]
7. DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release.
Ichikawa J; Dai J; Meltzer HY
Brain Res; 2001 Jul; 907(1-2):151-5. PubMed ID: 11430898
[TBL] [Abstract][Full Text] [Related]
8. Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex.
Pehek EA
Synapse; 1996 Sep; 24(1):12-8. PubMed ID: 9046072
[TBL] [Abstract][Full Text] [Related]
9. 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine.
Schmidt CJ; Fadayel GM; Sullivan CK; Taylor VL
Eur J Pharmacol; 1992 Nov; 223(1):65-74. PubMed ID: 1362159
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
Kehne JH; Baron BM; Carr AA; Chaney SF; Elands J; Feldman DJ; Frank RA; van Giersbergen PL; McCloskey TC; Johnson MP; McCarty DR; Poirot M; Senyah Y; Siegel BW; Widmaier C
J Pharmacol Exp Ther; 1996 May; 277(2):968-81. PubMed ID: 8627580
[TBL] [Abstract][Full Text] [Related]
11. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner.
Liégeois JF; Ichikawa J; Meltzer HY
Brain Res; 2002 Aug; 947(2):157-65. PubMed ID: 12176156
[TBL] [Abstract][Full Text] [Related]
12. The atypical antipsychotic sertindole enhances efflux of dopamine and its metabolites in the rat cortex and striatum.
Watanabe M; Hagino Y
Eur J Pharmacol; 1999 Feb; 367(1):19-23. PubMed ID: 10082260
[TBL] [Abstract][Full Text] [Related]
13. M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro.
Arvanov VL; Wang RY
Neuropsychopharmacology; 1998 Mar; 18(3):197-209. PubMed ID: 9471117
[TBL] [Abstract][Full Text] [Related]
14. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice.
Wang RY; Liang X
Neuropsychopharmacology; 1998 Jul; 19(1):74-85. PubMed ID: 9608579
[TBL] [Abstract][Full Text] [Related]
15. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo.
Willins DL; Berry SA; Alsayegh L; Backstrom JR; Sanders-Bush E; Friedman L; Roth BL
Neuroscience; 1999; 91(2):599-606. PubMed ID: 10366017
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study.
Ashby CR; Edwards E; Wang RY
Synapse; 1994 Jul; 17(3):173-81. PubMed ID: 7974200
[TBL] [Abstract][Full Text] [Related]
17. Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex.
Pehek EA; Bi Y
Prog Neuropsychopharmacol Biol Psychiatry; 1997 May; 21(4):671-82. PubMed ID: 9194148
[TBL] [Abstract][Full Text] [Related]
18. 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex.
Ichikawa J; Dai J; Meltzer HY
Brain Res; 2002 Jun; 939(1-2):34-42. PubMed ID: 12020849
[TBL] [Abstract][Full Text] [Related]
19. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats.
Kehne JH; Ketteler HJ; McCloskey TC; Sullivan CK; Dudley MW; Schmidt CJ
Neuropsychopharmacology; 1996 Aug; 15(2):116-24. PubMed ID: 8840347
[TBL] [Abstract][Full Text] [Related]
20. In-vivo effects of the 1,2,4-piperazine derivatives MM5 and MC1, putative 5-HT agonists, on dopamine and serotonin release in rat prefrontal cortex.
Iskra-Jopa J; Gołembiowska K; Dziubina A; Cybulski M; Duszyńska B; Chilmonczyk Z
J Pharm Pharmacol; 2005 Feb; 57(2):205-11. PubMed ID: 15720784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
